

## **Pectin Matrix As Oral Drug Delivery Vehicle for Colon Cancer Treatment**

Tin Wui Wong,<sup>1,2</sup> Gaia Colombo,<sup>3</sup> and Fabio Sonvico<sup>4</sup>

<sup>1</sup>Non-Destructive Biomedical and Pharmaceutical Research Centre, Universiti Teknologi MARA, 42300, Puncak Alam, Selangor, Malaysia.

<sup>2</sup>Particle Design Research Group, Faculty of Pharmacy, 42300, Puncak Alam, Selangor, Malaysia.

<sup>3</sup>Department of Pharmaceutical Sciences, University of Ferrara, 44100, Ferrara, Italy.

<sup>4</sup>Department of Pharmacy, University of Parma, 43100, Parma, Italy.

**Corresponding Author:** Tin Wui Wong, Faculty of Pharmacy, Universiti Teknologi MARA, 42300, Puncak Alam, Selangor, Malaysia, Tel: (60) 3-32584691; E-mail: wongtinwui@salam.uitm.edu.my

## **ABSTRACT**

Colon cancer is the fourth most common cancer globally with 639,000 deaths reported annually. Typical chemotherapy is provided by injection route to reduce tumour growth and metastasis. Recent research investigates the oral delivery profiles of chemotherapeutic agents. In comparison to injection, oral administration of drugs in the form of a colon-specific delivery system is expected to increase drug bioavailability at target site, reduce drug dose and systemic adverse effects. Pectin is suitable for use as colon-specific drug delivery vehicle as it is selectively digested by colonic microflora to release drug with minimal degradation in upper gastrointestinal tract. The present review examines the physicochemical attributes of formulation needed to retard drug release of pectin matrix prior to its arrival at colon, and evaluate the therapeutic value of pectin matrix in association with colon cancer. The review suggests that multi-particulate calcium pectinate matrix is an ideal carrier to orally deliver drugs for site-specific treatment of colon cancer as 1. crosslinking of pectin by calcium ions in a matrix negates drug release in upper gastrointestinal tract, 2. multi-particulate carrier has a slower transit and a higher contact time for drug action in colon than single-unit dosage form, and 3. both pectin and calcium have an indication to reduce the severity of colon cancer from the implication of diet and molecular biology studies. Pectin matrix demonstrates dual advantages as drug carrier and therapeutic for use in treatment of colon cancer.

**KEYWORDS:** Colon cancer, oral drug delivery, pectin.

## **COLON ANATOMY AND PHYSIOLOGY**

The term colon refers to the lower part of gastrointestinal tract, extending from ileocecal junction to anus (Fig. 1). It is divided into several sections, i.e. cecum, ascending colon, transverse colon, descending colon, sigmoid colon and rectum with characteristic lengths of 6 to 7, 20, 45, 30, 40 and 12 cm respectively and an average internal diameter of 6 cm (1,2). The main role of colon is consolidation of intestinal content into feces by absorption of water and electrolytes. The colon has a large absorptive capacity of which 2000 ml of fluid entering the colon each day will be absorbed by more than 90 % (1). In healthy human subjects, sodium and chloride ions are usually absorbed and potassium and bicarbonate ions are usually secreted. Fluid and electrolyte absorption is assisted by segmental contraction which circulates chyme across colonic mucosa.

The colon epithelium is covered and protected by mucus of which the major glycoprotein constituents are mucins (3). Two structurally and functionally distinct classes of mucins have been identified: secreted gel-forming mucins (MUC2, MUC5AC, MUC5B and MUC6) and transmembrane mucins (MUC1, MUC3A, MUC3B, MUC4, MUC12 and MUC17). The mucins contain a high content of carbohydrates which are present in the form of clustered oligosaccharides linked to tandem repeat peptides rich in threonine, serine and proline. They possess a high molecular weight, are resistant to degradation in intestinal tract and recognizable by a number of antibodies and lectins.

The colon contains an almost neutral and reducing medium. In healthy human subjects, the part of gastrointestinal tract which exhibits the highest pH level is terminal ileum ( $7.5 \pm 0.5$ ) (1). On the contrary in the colon, pH is reduced to  $6.4 \pm 0.6$ ,  $6.6 \pm 0.8$  and  $7.0 \pm 0.7$  at proximal, middle and distal colon regions respectively (1,2,4). Under normal physiological condition of healthy human subjects, the colon exhibits irregular alternation of quiescence, non-propagating, segmental

contractions and far less frequent propagated contractions (5). While segmental and propagated contractions predominate in mid-region and distal colon respectively, retrograde movements have been demonstrated at proximal colon and contribute to increase mass retention in ascending colon and cecum thereby promoting fermentation, electrolyte and water resorption (1).

A dosage form that does not undergo disintegration/dissolution in the upper gastrointestinal tract could require 4 to 12 hours to reach colon following oral administration (1). In comparison to upper gastrointestinal tract, the transit of chyme through colon is slower and the total transit time is highly variable and affected by several factors. Under normal condition, the mean total colonic transit time is 35 hours as indicated by radiopaque marker technique. The mean segmental transit times of right (ascending and part of transverse), left (part of transverse and descending) and rectosigmoid colon are 11.3, 11.4 and 12.4 hours respectively. The total colonic transit time is shorter in male than female. Smaller dosage forms such as microparticulate systems (granules, pellets, beads), travel at a slower rate in colon than larger units (tablets) unlike gastric emptying profile of the same dosage forms (1-4). The transit rate of colonic content does not exceed the doubling time of bacteria (6). The bacteria can proliferate and ferment the chyme along its colonic passage.

## **COLONIC MICROFLORA**

The human colon consists of over 400 distinct species of bacteria with a population of  $10^{11}$  to  $10^{12}$  CFU/ml and a small number of fungi (1,2,5,6). A breakdown of microbial count with respect to aerobic or facultative bacteria, fungi and anaerobic bacteria is summarized in a review by Vandamme et al. (2). In a healthy adult, the microbial community consists of autochthonous and allochthonous microbes (6). The main species include *Bacteroides*, *Bifidobacterium*, *Eubacterium* and *Lactobacillus* (2,5,6,7). These bacteria produce reductive and hydrolytic enzymes which are active in carbohydrate and protein fermentation, bile acid and steroid transformation and

metabolism of xenobiotic substances (5). The proximal colon has the highest rate of microbial growth as it receives the highest concentration of energy source (1). The primary source of nutrition for these anaerobic bacteria is carbohydrates such as non-starch polysaccharides **from** the intestinal **chyme** (5). The non-starch polysaccharides are fermented during transit through colon via enzymatic action of  $\alpha$ -L-arabinofuranosidase,  $\beta$ -D-fucosidase,  $\beta$ -D-galactosidase,  $\beta$ -D-glucosidase and  $\beta$ -xylosidase (5,6). Polysaccharide enzymatic breakdown is greater in proximal colon than distal colon, while is negligible in stomach and small intestine (1,5).

The end products of fermentation include short chain fatty acid, carbon dioxide, hydrogen, methane and hydrogen sulphide (1). The highest level of short chain fatty acid is produced at right colon (127 mM) with a molar ratio distribution of 57:22:21 for acetate, propionate and butyrate respectively (2). The total short chain fatty acid concentrations at transverse and left colon are 117 and 90 mM respectively, with corresponding molar ratio distributions of 55:22:23 and 57:21:22 for acetate, propionate and butyrate. The short chain fatty acids are responsible for the pH lowering observed in colon, nonetheless they are rapidly absorbed from large intestine stimulating at the same time sodium and water absorption (6). The fatty acids are utilized as energy source of intestinal epithelium. The butyrate in addition regulates nucleic acid metabolism of epithelial cells and maintains the health of epithelium. In **human**, the composition of colonic bacteria population and enzymes levels are influenced by age, diet, geographic prevalent, intestinal pH, motility and food content (2,5). **Diseases, drugs and bacterial metabolites can greatly affect host microflora profiles.**

## **COLON CANCER**

Colon is liable to a number of pathological conditions, namely infections, inflammatory bowel diseases (Crohn's disease and ulcerative colitis), irritable bowel syndrome and cancer. Colon

cancer, commonly known as colorectal cancer or large bowel cancer refers to cancerous growth in colon, rectum or cecum. A total of 639,000 deaths related to colon cancer are reported worldwide each year (8). Colon cancer is the fourth most common form of cancer globally. Colon cancer is reckoned to be a disease of affluence, as it occurs most frequently in North America, Australia, New Zealand, Japan and Western Europe (9-12).

It is generally accepted that colon cancer is mainly attributable to diet in one way or another (9,11,13). Several additional risk factors have been related to colon cancer, including gender and ethnicity with a higher risk in male than female and black than white respectively (9-11,14), old age (10,11,13), presence of adenomatous polyps (10,11,13), previous history of ovary, uterus or breast cancer (15), smoking and alcohol drinking habits (9,10,16), physical inactivity (9,11), contraction of specific strains of human papilloma viral infection (15), *Streptococcus bovis* bacteremia and inflammatory bowel diseases (10,11,13), particularly ulcerative colitis. Administration of exogenous hormones such as estrogen in hormone replacement therapy, as well as, regular use of non-steroidal anti-inflammatory drugs, are reported to exert some protective effects against colon cancer (9-11,17,18).

Sixty to eighty percent of colon cancer cases do not appear to be attributed to inherited symptoms or familial tendency, and are known as sporadic cancer (19). The risk of developing sporadic colon cancer is significantly modulated by environmental factors. The majority of sporadic colon cancer manifests via tumour suppressor/chromosomal instability pathway which could involve the mutation/loss of *APC* (adenomatous polyposis coli), *p53*, *DCC* (deleted in colonic cancer), *SMAD 4* and *K-ras* genes, as well as, activation of telomerase (Fig. 2) (10,18-21). Ten to fifteen percent of sporadic colon cancer express via microsatellite pathway which involves mutation of *MMR* (mismatch repair) genes (10,19). Ninety five percent of all malignant tumours of colon are

carcinomas (22). Early colon carcinomas are limited to submucosa as polypoid lesion, pedunculated, semipedunculated or sessile (14,22). Flat lesion with no or slight elevation of not more than twice the mucosa height can exist possibly with slight central depression. Advanced carcinoma invades beyond submucosa and is frequently found ulcerated with sharply demarcated margin or to a lesser extent as polypoid. Adenocarcinoma and mucinous adenocarcinoma represent 90 to 95 % of carcinomas. Some adenocarcinomas produce abundant mucus. These carcinomas remain as adenocarcinomas unless mucus contributes to more than 50 % of tumour bulk. The severity of carcinoma is indicated by histopathological grading G1 to G4 which ranges from well differentiated carcinoma with cellular features closely resemble to normal epithelium to undifferentiated carcinoma with no glandular and squamous differentiation at all. The anatomical extent of colon carcinoma is described by Dukes classification where A, B and C denote tumour invading submucosa, muscularis and lymph node respectively, and **D denotes distant metastasis** or TNM (Tumour Node Metastasis) system with T grades the level of tumour invasiveness, N grades the involvement of regional lymph node and M grades the level of distant metastasis (11,13,21).

Surgery remains the primary mode of colon cancer treatment with chemotherapy and/or radiotherapy recommended upon the nature and extent of severity of disease. Chemotherapy can be provided after surgery as adjuvant, before surgery as neo-adjuvant or as primary therapy to reduce tumour size and growth as well as the likelihood or propensity of metastasis. Chemotherapy is given as adjuvant when the cancer has spread to lymph nodes. Typical regimen of adjuvant chemotherapy is based on the combination infusion of 5-fluorouracil, leucovorin and oxaliplatin (11). In case of metastasis, the chemotherapy is given as a primary treatment and is represented by a combination of infusional 5-fluorouracil, leucovorin and oxaliplatin with bevacizumab or 5-fluorouracil, leucovorin and irinotecan with bevacizumab (15,23,24). The majority of metastases arising from colon cancer is confined to liver (11). Regional delivery of chemotherapy can be performed via hepatic artery, as this has been known for years to supply blood to micrometastasis (25).

Alternatively, the chemotherapeutic agents can be administered via the oral route. Many oral chemotherapeutic agents, mainly fluorinated pyrimidines, have been developed and evaluated for the treatment of advanced and curatively resected colon cancer (26). In comparison to injection, oral administration of anti-cancer agents is expected to improve the quality of life of patients and increase the cost-effectiveness of treatment through reducing the duration of hospitalization. Possible examples of these anti-cancer agents are 5-fluorouracil, hexycarbamoyl-5-fluorouracil (carmofur), uracil/tegafur, uracil/tegafur/leucovorin and N<sup>4</sup>-pentoxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine) (11,24,26). Oral administration of uracil-tegafur with leucovorin or capecitabine demonstrates approximately equal efficacy and similar median survival time, but less mucositis, neutropenia and alopecia than intra-venous 5-fluorouracil (11,24). Various positive clinical outcomes on usage of oral chemotherapeutic agents for treatment of colon cancer have been reviewed by Sakamoto et al. (26). The transformation of injectable to oral route is deemed to be a feasible approach in drug administration. Indeed, the orally administered capecitabine has been recommended clinically as an equivalent alternative to intravenously administered 5-fluorouracil-leucovorin (27).

### **COLON-SPECIFIC ORAL DRUG DELIVERY SYSTEM**

With respect to the treatment of colon cancer by orally administered chemotherapeutic agents, it has been suggested by several authors that if the drug is released from the dosage form specifically in the colonic region, it can achieve maximal pharmacological effect. Indeed, colon targeted drug delivery can increase drug bioavailability at target site, possibly allowing for the reduction of the administered dose and decrease of systemic side effects (4,6). Delivering the drug specifically to the colon is ideal for the exploitation of new biotechnology drugs, such as peptides or protein drugs, due to minimized acidic and enzymatic drug degradation otherwise predominant in the upper



gastrointestinal tract. The degree of drug absorption can be enhanced by exploiting the greater colon susceptibility to absorption enhancer effects and prolonged dosage form transit time in comparison to upper gastrointestinal tract (28). However, to succeed in colon targeting it is imperative to deliver drugs at adequate local concentration and without premature drug release/loss in the upper gastrointestinal tract.

Broadly, five colon-specific drug delivery technologies have been developed and evaluated for their suitability over the years. They all have a common key concept of exploiting unique physiological features of the gastrointestinal tract to obtain system activation and drug release only upon reaching the colonic region. They are prodrug/azo-polymer systems, time-dependent systems, pH-dependent systems, pressure-dependent systems and microbial triggered systems (1,2,4,6,29,30).

Azo-polymers are relatively stable in upper gastrointestinal tract. The azo bonds can resist chemical and enzymatic actions in stomach and small intestine. Nevertheless, the hydrophobic azo-polymers undergo slow degradation by enterobacteria making the intended drug release at specific site delayed (31). However, a risk has been evidenced that azo-polymeric matrices degradation results in the formation of toxic by-products, making such systems unsuitable for long-term treatments. The prodrug approach, on the other hand, is restricted by the availability of functional groups on drug moiety for chemical linkage and new drug entity requiring lengthy evaluation from a regulatory point of view prior to its use in market.

pH-dependent systems are commonly formulated using enteric coating techniques (32). However, the small intestine and large intestine do not have a markedly different pH environment and, as a consequence, the reproducibility of drug release at a well-defined site from a pH-dependent system can be poor. In other words, the use of enteric coated dosage form may be accompanied by

premature drug release in the small intestine. This depends also on the profile of gastrointestinal motility which varies among individuals and disease/dietary conditions which lead to variations in pH of intestine.

In a similar way, changes in motility, pH and microflora activity of the gastrointestinal tract affect the site specificity of time-dependent systems. Time-dependent systems exploit gastro-intestinal transit time as a tool to tune drug delivery to the colon by means of a suitably delayed release profile (33). It is practically difficult to utilize transit time as a measure to target drug delivery of these systems at colon. The suitability of pressure-dependent systems is a function of the reproducibility in pressure and duration of peristaltic waves as well as of disease condition (34). The high pressure phases in colon are known to be infrequent and follow circadian rhythm with maximum frequency after waking, meals and with defecation. The success rate of drug release from a pressure-dependent system in colon is therefore low or unpredictable.

Colon-specific drug delivery by means of prodrugs, azo-polymers, time-, pH- and pressure-sensitive approaches has respective pros and cons. Each of them encounters limitations in degree of site specificity, toxicity, ease of preparation and reproducibility of performance. In comparison to these approaches, drug release triggered by colonic microflora is envisaged to have a higher degree of site selectivity. Polysaccharides can be selectively degraded by colonic enzymes and their use as drug vehicle can trigger drug release to start in the colon. The degradation of polysaccharides by microflora exhibits a relatively consistent pattern across diverse human population (35), thus assuring the reproducibility of drug release performance of polysaccharide-based drug carriers. Using naturally occurring dietary polysaccharides, the issues of toxicity and safety are minimized. The main saccharolytic species in colon are *Bacteroides* and *Bifidobacterium* (6). The success of polysaccharides as drug carriers also lies in their ability to hydrate and swell creating a diffusion barrier during its gastrointestinal transit. Upon arrival at colon, the hydrated vehicle permits the

access of colonic bacteria/enzymes to degrade the polysaccharide network and release the drug at the intended site. Examples of polysaccharides which are potentially useful in the formulation of colon-specific drug delivery systems include alginate, amylose, arabinogalactan, arabinoxylan, cellulose, chitosan, chondroitin sulphate, dextran, guar gum, locust bean gum, inulin, karaya gum, laminarin, pectin, starch, tragacanth gum, xanthan gum and xylan (1,2,4,6,29,36).

## **PECTIN AND COLON CANCER**

Pectin is a natural heteropolysaccharide with at least 65% by weight of galacturonic acid units (37). It is made of 1,4 linked  $\alpha$ -D-galactosyluronic acid residues and a range of neutral sugars such as rhamnose, galactose, arabinose and lesser amounts of others (37,38). Pectin is available in the form of free acid, simple salt such as sodium, potassium and calcium salts, methyl ester, acetyester, feruloyl ester or amidated polysaccharide (36,37,39,40). Pectin is polymolecular and polydisperse. It contains a few hundreds to about 1000 saccharide units in a chain like configuration, corresponding to an average molecular weight between 50000 and 150000 daltons (41).

Pectin is suitable for use as colon-specific drug delivery vehicle in treatment of colon cancer and other colon diseases as it is selectively digested by microflora in colon and exhibits potential to prevent colon cancer from the implication of diet (42). Being a soluble dietary fiber, pectin is reported to increase the transit time through gastrointestinal tract, fecal bulk, bile acid excretion and short chain fatty acid production. Unlike insoluble fiber such as cellulose, it undergoes almost 100 % fermentation in colon (43). Fermentation of pectin leads to the generation of short chain fatty acids (42,43). The short chain fatty acids are the primary energy source of colonocyte (12,43,44). Moreover, these fatty acids lower the colonic pH, which is protective against colon cancer (42,43,45). In fact, epidemiology studies indicated that colon cancer subjects have a fecal pH of 7, whereas normal subjects have a fecal pH of 6.5. 7- $\alpha$ -dehydroxylase is the bacterial enzyme which converts primary bile acids into secondary bile acids such as lithocholic acid and deoxycholic acid,

known as promoter of colon cancer. Though debatable, the lowering of pH obtained by pectin fermentation can reduce the risk of colon cancer by diminishing the production of secondary bile salts, via inhibiting the activity of 7- $\alpha$ -dehydroxylase at a pH below 6.5 and by simultaneously decreasing free bile acid solubility (43,45). The level of bile acids can be further lowered by pectin via increasing their excretion in feces (42,46).

In addition to colonic pH lowering effects, short chain fatty acids decrease colon hyperproliferation induced by deoxycholate in association with reduced expression of c-Fos and c-Jun (42). They have shown to promote apoptosis in a variety of colon tumour cell lines and are able to depress proliferation of tumour cells *in vivo* (12,42,43). The butyrate induces apoptosis in tumour cells which lack a functional p53 pathway via a caspase-dependent process (12). It downregulates bcl-2 oncogene thereby removes the barrier to apoptotic cell death (16). The butyrate induces histone hyperacetylation via the inhibition of histone deacetylase (12,18,43). Acetylation of histone favors an open, transcriptionally active chromatin configuration which in turn facilitates the expression of pro-apoptotic genes.

While low methoxyl pectin, high methoxyl pectin and citrus pectin are found to increase the risk of colon tumour (47,48), apple pectin and citrus pectin have been reported lately to decrease the number and incidence of colon tumour (49,50). Pectins and pecticoligosaccharides are found to increase the apoptosis frequency of colonic adenocarcinoma cell line HT29 (51). Dietary supplementation of pectin indicates that pectin can suppress colon cancer significantly and exert anti-proliferative effect in mouse distal colon (52,53). Pectin can negate colon cancer via inhibiting galectin-3 biological functions. Galectin-3 is a chimeric gene product with a monomer subunit of approximately 30000 daltons which undergoes noncovalent homodimerization (3). It is a  $\beta$ -galactoside binding protein which can be found in the cytoplasm and nucleus, on the cell surface,

and is secreted by tumour cells. Galectin-3 mediates cell-cell adhesion to reduce apoptosis incurred by anoikis, and to induce initial adhesion of cancer cells to endothelium and subsequent tumour cell homotypic aggregation (Fig. 3) (3,54-56). It promotes tumour cells to interact with extracellular matrix proteins in development of a secondary tumour growth, clonogenic survival of cancer cells, and stimulates endothelial cell morphogenesis and angiogenesis necessary for tumour growth. Specific gene expression and anti-apoptotic activity are regulated by nucleus and cytoplasmic galectin-3 respectively, whereas extracellular galectin-3 mediates cell migration, cell adhesion and cell-cell interaction through its carbohydrate binding property. Galectin is expressed at higher levels in colon cancer than normal colon. It binds to colonic MUC 2 mucin with altered carbohydrate structure. Carbohydrate or polysaccharide mediated interference with galectin-3 binding to mucin can lead to therapeutic or prevention advantages in colon cancer. Modified citrus pectin, low methoxyl pectin and high methoxyl pectin are reported as antagonists to galectin-3 (3,54-58). Modified citrus pectin has shown to reduce the growth and metastasis of colon tumour (3,56-58). Orally administered modified citrus pectin at 0.8 and 1.6 mg/ml for 20 days to balb-c mice implanted with colon-25 tumours exhibits a dose-dependent reduction in tumour size (57). The modified citrus pectin has a potential to raise the apoptotic response of tumour cells to chemotherapy (56). The summative observation indicates the likelihood of pectin being utilized as drug, matrix vehicle and therapeutic sensitizer of anti-cancer agents.

Citrus pectin modified by heat treatment is reported to lead to significant levels of tumour cell apoptosis comparable to fractionated pectin powder (56). pH treatment of modified citrus pectin is critical to reduce cell-cell adhesion in the development of tumour though it is reported that mild base treatment removes ester linkages of pectin and destroys its apoptotic activity. Pectin exhibits a higher strength of mucoadhesion on large intestinal mucosa than small intestinal mucosa (59). The mucoadhesion property of pectin is promoted by high degree of esterification and large molecular

weight attributes of pectin. High esterified pectin tends to form gel network with endogenous mucin on the surfaces of colonic mucosa (60). The strong tendency of pectin to interact with large intestinal mucosa is expected to interrupt the biochemical processes mediating cell-cell adhesion in tumour growth. Modification or processing of pectin by means of heat or pH treatment shall avoid excessive molecular chain breakdown or de-esterification of pectin which can translate to a loss of its mucoadhesiveness and therapeutic function.

### **PECTIN AS COLON-SPECIFIC ORAL DRUG DELIVERY VEHICLE**

Pectin is completely fermented in colon by microflora with low esterified pectin being fermented faster than high esterified pectin (61). It appears that only a partial degradation is possible at the pH 2 to 4 conditions of stomach via side chain hydrolysis and at pH 5 to 6 conditions of small intestine via  $\beta$ -elimination of main chain or de-esterification (61,62). Nonetheless, pectin is an aqueous soluble polymer. The matrix made of pectin is prone to swelling as well as erosion in aqueous medium leading to premature drug release at upper gastrointestinal tract and thereby defeating its ability as colon-specific drug delivery vehicle.

The pectin-based matrix is available as single-unit dosage form such as tablet or multiple-unit dosage form, namely beads, pellets and microparticles. In designing colon-specific drug delivery systems, numerous formulation approaches have been taken in the past years to prevent pectin-based matrix from undergoing early drug release in the upper gastrointestinal tract (Fig. 4). The pectin in matrix has been subjected to crosslinking by di- or multi-valent cations, coacervation with an oppositely charged polyelectrolyte, mixing with viscous polymer and/or calcium salt, or coating with viscous, pH resistant or poorly water-soluble polymer, coacervate and/or complex to reduce its drug dissolution propensity in aqueous medium prior to reaching the colon (Table 1). Pectin, in combination with a crosslinking agent or a polymer, may also be employed itself as a delayed-

release coat to be applied onto a drug core via film or compression coating technique. In particular, multiple coat layers can be applied onto the drug core and these coats can vary in their chemical composition in order to retard/modulate drug release at different sites of upper gastrointestinal tract. Pectin has also been used to prepare prodrugs which will release the free drug upon arrival at colon. Table 1 summarizes several types of pectin-based colon-specific dosage forms and their associated formulation mechanisms. In addition to the anti-cancer agents 5-fluorouracil and methotrexate, anti-inflammatory drugs, antibiotics, anti-nociceptive agents and enzymes have been formulated in the form of pectin-based matrix for colon delivery. A schematic flowchart in relation to processing technology employed in crosslinking, coacervation, compression and coating of various formulations is shown in Fig. 5.

The proposed formulation strategies to prevent premature drug release from pectin-based colon-specific dosage form exploit a number of mechanisms as follow:

1. enhancement of hydrophobicity
2. reduction of aqueous solubility
3. enhancement of physical strength
4. enhancement of viscosity
5. reduction of swelling capacity
6. reduction of erosion capacity

of the pectin-based matrix or coat. A functional colon-specific dosage form must not exhibit premature drug release at upper gastrointestinal tract. It must nevertheless be able to hydrate, swell and absorb enzyme- or microflora-rich fluids in colon. The pectinolytic enzymes would then digest the pectin components of matrix or coat of a dosage form thereby initiating drug release.

High methoxyl pectin has been advocated as the polymer of choice because it is inherently less water soluble than low methoxyl pectin (75,76,86). However, it is reported that low methoxyl pectinate beads coated with high methoxyl pectin exhibit a higher propensity of drug release than uncoated beads (92). This is ascribed to prolonged exposure of drug core to moist high methoxyl pectin layer during coating process. It results in drug migration to the surface and leads to a burst release effect upon erosion and dissolution of the high methoxyl pectin coat. Low methoxyl pectin is prepared by hydrolytic demethylation of high methoxyl pectin (83). This reaction is known to reduce the molecular weight and chain length of pectin. Shorter chain length of pectin is characterized by its higher aqueous solubility, unstable polymeric network and faster drug release. In conjunction with colon-specific dosage form prepared using chitosan and/or multi-valent cationic salt, low methoxyl pectin is nevertheless preferable as it is able to interact with chitosan or cationic salt to a greater extent than high methoxyl pectin due to the availability of a higher fraction of free carboxylic acid groups.

Crosslinking of pectin with calcium ion or zinc ions, as well as, coacervation/complexation with polymers such as chitosan and/or Eudragit™ decreases the solubility, swelling and erosion extent of the polymer, but increases the mechanical strength and hydrophobicity of the dosage form. An increase in hydrophobicity of the dosage form due to charge neutralization reduces its tendency to interact with dissolution medium thereby lowering the rate and extent of drug release. A reduction in solubility, swelling and erosion and an increase in mechanical strength, following complex or crosslink formation, minimize the breakdown of dosage form, the generation of surface pore or cracks and similarly reduce the abrupt release of drug from dosage form to surrounding dissolution medium. The hydrophobicity and drug release retardation capacity of colon-specific dosage form can be further promoted by coating the matrix with ethylcellulose, a water-insoluble polymer. The



mechanical strength of dosage form can be modulated and enhanced through blending of pectin with hydroxypropylmethylcellulose or dextran. The combination with hydroxypropylmethylcellulose or dextran can increase the gel viscosity of the hydrated dosage form. It reduces the erosion propensity of matrix thereby lowering drug release.

The chemical composition of the matrix and/or coat polymer is the key parameter affecting the drug release pattern of colon-specific dosage form. Sustaining drug release will be less possible when calcium pectinate is used instead of pectin to complex with Eudragit™ (95). The calcium pectinate has a lower fraction of carboxylate moiety than pectin as some of its active sites are occupied by calcium ions. The level of calcium pectinate-Eudragit™ complexation is lower than that of pectin-Eudragit and the formed complexes are less able to retain drug within the matrix. The lowest drug release can be obtained when a coat is made of a high content of pectin complexed to chitosan, using low methoxyl pectin and highly deacetylated chitosan which provide a substantial fraction of carboxylate and amino moieties respectively for coacervation reaction (96). In any case, coacervation of pectin with chitosan however does not negate the drug release of pectin-based dosage form in response to pectinolytic enzymes (76,81).

In drug delivery system with coat composed of pectin and hydrophobic polymer, the digestion of pectin results in the formation of pores for drug release (72,73,75,85,95). The fraction of hydrophobic polymer in the coat must not be excessively high in order for pectin to hydrate for enzymatic digestion to take place at colon. It must not be too low as this will bring about premature drug release. The optimal pectin content has been reported to constitute less than 20 % in the composite (36). In coat made of complex of water-soluble polymers, the action of pectinolytic enzymes on the coat complex gives rise to pectin leaching and drug release in colon (86). The hydrophilic polymer counterpart of pectin, once released from complex, similarly becomes freely

solvated, swells and leads to distortions in coat thereby further facilitating drug release. Enzymatic degradation of pectin components forms the primary mechanism of colon-specific drug release. Nevertheless, the leaching of pectin components from coat may suppress the formation of hydrated pectin channels (87,92). The undigested coat on matrix can be reconstructed via distension, plugging up pores, reducing free volume between polymer chains and preventing drug release. The restructuring of coat is possible when glass transition temperature of coat is close to temperature of dissolution medium and it can be lowered when polymers are placed in a liquid environment. In accentuation of drug release from the core to the surrounding colonic medium, a disintegrant such as crosslinked polyvinylpyrrolidone can be added to such matrix (72). The digestion of pectin by pectinolytic enzymes is accompanied by water influx into core and build-up of pressure by crosslinked polyvinylpyrrolidone onto surrounding coat/matrix substances, thus accelerating the release of drug in colon.

Calcium ions are commonly used as crosslinking agent in preparation of pectin-based colon-specific dosage form. The incorporation of a calcium salt into a pectin matrix enhances the susceptibility of pectin to enzymatic digestion in human colon since many pectinases have shown to be stimulated by or have an absolute requirement for calcium ions for their activity (36,63,64). The calcium pectinate matrix is found to release the major part of drug in intestinal medium (67,69,77). Generally, the use of a higher calcium ion content can reduce drug release while the matrix travels along the gastrointestinal tract towards colon and it could provide sigmoidal drug release pattern (63,64).

Lately, zinc ions have been adopted as crosslinking agent of interest. The zinc ion crosslinked pectin matrix releases drug at a lower rate than the calcium ion crosslinked sample (67,77,78). In comparison with calcium ions, zinc ions form a more extensive crosslink with pectin and reduce the degree of rehydration and molecular porosity of matrix to a greater extent. Rapid drug release from

calcium ion crosslinked matrix is presumably due to a greater level of solvent penetration into the calcium pectinate network followed by a greater propensity for ion exchange of calcium with sodium and potassium ions. The monovalent ions displace calcium ions from the gelled structure and transform insoluble calcium pectinate into soluble pectin which has less drug release retardation capacity.

## **PECTIN-BASED COLON-SPECIFIC ORAL DRUG DELIVERY SYSTEM AND COLON CANCER**

Over the past five years, *in vivo* assessments indicate that colon-specific pectin-based oral dosage forms can be designed primarily through coating of drug matrix with pectin-ethylcellulose or Eudragit film (85,91). The early drug release in gastrointestinal tract is negated by coat hydrophobicity and reduced matrix solubility. The majority of drug is released or accumulated at the colonic region of intestinal tract. Pharmacokinetically, the propensity of drug absorption at colon can be low due to reduced absorption surface area and low drug permeability across colonic barrier. Some of the released drug may still be located in the colon lumen 24 hours after oral administration of matrix due to slow transit (85). Low drug absorption may be undesirable for systemically acting drugs. In colon cancer chemotherapy, low plasma drug concentration can nevertheless increase the safety margin of the treatment by lowering peak plasma drug levels and sustaining tumor exposure to the drug. Low plasma drug concentrations coupled to prolonged exposure to high local colonic drug concentration could facilitate DNA-directed action of the drug, which contributes to the anti-cancer effect.

5-fluorouracil has been loaded into pectin microspheres by means of emulsion dehydration technique (91). Briefly, a w/o emulsion is first obtained by mixing the solution mixture of drug and pectin with isooctane. This is followed by dehydration of dispersed phase by acetone to produce the microspheres. The formed microspheres, having a mean diameter between 25 and 30  $\mu\text{m}$ , are then

coated with Eudragit S100 by an oil-in-oil solvent evaporation method. The coated microspheres are able to prevent the release of 5-fluorouracil at pH 1.2 and 4.5, otherwise observed for uncoated matrix. These microspheres can efficiently deliver drug to the colon after 6 to 8 hours of administration in rats. In another work reported by Wei et al. (85), 5-fluorouracil is encapsulated in pellets by means of extrusion-spheronization technique using microcrystalline cellulose as processing aid. The formed pellets are subsequently coated with pectin and ethylcellulose using the fluid-bed coating technique. *In vivo* bioavailability analysis of coated pellets indicates that a  $T_{max}$  of 14 h is obtainable when compared to uncoated samples which are characterized by a short  $T_{max}$  of 0.75 h. Formulation of 5-fluorouracil in these coated structures can delay the release of drug in gastrointestinal tract.

Recent reports on pectin-based colonic delivery system containing 5-fluorouracil and methotrexate indicate that sustained-release pellets and microparticles are preferred as oral dosage form to deliver chemotherapeutic agents in colon cancer (80,84,85,91). Unlike gastric transit, small dosage forms show a slower colon transit than large dosage forms (1). Prolonged colonic retention of dosage form and/or consistent local colonic exposure to anti-cancer drug is more easily attainable by using multiple-unit particulate system such as beads, pellets and microparticles as drug delivery systems instead of single-unit tablets (often large because of high drug doses).

Crosslinking agents have been part of the formulation for many pectin-based multi-particulate colon-specific drug delivery systems. In spite of recent reports favoring the use of zinc ions, calcium ions will possibly remain as the mainstream crosslinking agent as they promote pectinolytic enzymatic degradation of pectin and exhibits biological properties which aid to counteract the development of colon cancer. In a recent work of Chaurasia et al. (80), calcium pectinate beads in the size range of 20 to 30  $\mu\text{m}$  are produced by modified emulsification method using calcium

chloride as crosslinking agent. These beads have a good encapsulation efficiency of methotrexate (up to 74 %) and release only 8 % of loaded drug when they are incubated for 5 h in simulated gastric fluid followed by enzymeless simulated intestinal fluid. The majority of drug release only when pectinase or cecal rat content is present in the simulated intestinal fluid, demonstrating that the pectinate matrix crosslinked by calcium ions is still an efficient carrier to target the release of anti-cancer drug at colon through exploiting the physiological features of colonic environment.

The role of calcium in colon cancer has been evaluated in animals, epidemiologic studies and human intervention studies (97). Though there is no clear relationship between calcium intake and colon cancer development, dietary supplementation with calcium has been found to reduce adenoma size and number (18). High calcium and vitamin intake increases apoptosis of colonic epithelium and may reduce risk of colon cancer (16-18,98). The capability of calcium to combat colon cancer is likely ascribed by its binding affinity to potentially carcinogenic free bile acids in colon.

Both pectin and calcium have indicated their biological significance in combating the development of colon cancer. The present review hitherto suggests that multi-particulate drug delivery system made of calcium pectinate can be an ideal carrier to orally administer and deliver chemotherapeutic agents to the colon for treatment of colon cancer, upon modification to prevent early drug release in the upper part of gastrointestinal tract. Both pectin and calcium should be the main excipients used in the formulation of the delivery system. These excipients can be used as matrix/coat substances. The success of chemotherapy is dependent on the ability of the delivery system to hinder premature drug release in the upper gastrointestinal tract, and be digested and released the loaded drug, possibly together with pectin and calcium at the site of disease. It is envisaged that the reproducibility of matrix/coat digestion and drug release at colon is an interplay effect of colonic

pH and microflora environment with the physicochemical properties of drug, pectin and other excipients of the dosage form. The composition of every individual microflora can fluctuate under illness and to a lesser extent be induced by dietary intervention (99). High risk of colon cancer is associated with the presence of *Bacteroides vulgatus* and *Bacteroides stercosis* in human. However, the exact complications brought about by microflora changes in presence of colon cancer on the performance of pectin-based drug delivery systems are not known and likely to remain elusive. One main reason for this is that the intestinal bacteria are adapted to an anaerobic environment (100). They are difficult or impossible to culture extra-intestinally for study. With the advent of genetic technology, only 1822 of more than 20000 rRNA gene sequences in GenBank are in fact documented as derived from human gastrointestinal tract, and 1689 are uncultured bacteria. Another issue is related to pH differences. The colonic mucosa pH is alkaline (pH = 8) and is similar on both sides of colon in healthy and colon cancer patients (101,102). Both healthy right colostomates and cancer patients have the same luminal pH at 7.6, but the fecal pH of healthy right colostomates is lower than that of colon cancer patients (pH = 6.6) (101). Variations in rate and extent of drug release from pectin-based dosage forms are deemed to be induced by different fecal pH environments at the proximal colon in diseased and healing states, and such variations are expected to be complicated by and/or be a resultant effect of concomitant changes of microflora composition during the treatment of colon cancer.

## **FUTURE ISSUES**

Continuing efforts to design pectin-based delayed-release dosage form for use in colonic drug delivery are undertaken by many researchers. Gelatin, alginate and xyloglucan are some polymers explored in formulation of pectin-based drug delivery system (103-106). The pectin-based dosage form has been recently subjected to treatment by microwave to evaluate the capacity of radiation to

further reduce the drug release propensity of matrix at upper gastrointestinal tract (107,108). Ongoing research is conducted to produce water-resistant pectin derivatives without compromising their susceptibility to microflora fermentation in the colon (36). Pectin receives an overwhelming attention on its practical applications and implications in drug delivery. Nonetheless, one shall highlight that there is no clear picture on the exact complex structure of pectin and the physicochemical attributes of pectin vary with its source and manufacturing process (37,56). Further work shall be conducted to characterize the physicochemical attributes of pectin and evaluate its structure-activity relationship with reference to colon-specific drug delivery. Pectin has shown an indication to be able to suppress colon cancer growth lately. The collective effectiveness of pectin as drug delivery vehicle, drug and/or therapeutic enhancer in colon-specific delivery of anti-cancer drugs requires verification. The distribution probability of cancer varies from one site to another site of colon and 99% of carcinomas occur singly (Fig. 1) (21). The possibility of pectin-based colon-specific dosage form to perform solely and precisely at a cancer site of an abnormal colon is a fascinating challenge for future pharmacutists. Polymers, other than pectin, require further investigation on their potential use as concurrent drug carrier and chemotherapeutic agent through a multi-disciplinary approach.

## **ACKNOWLEDGMENTS**

The authors wish to thank the Ministry of Higher Education, Malaysia for facility support (code: 0141903).

## REFERENCES

1. Watts PJ, Illum L. Colonic drug delivery. *Drug Dev Ind Pharm.* 1997;23(9):893-913.
2. Vandamme ThF, Lenourry A, Charrueau C, Chaumeil J-C. The use of polysaccharides to target drugs to the colon. *Carbohydr Polym.* 2002;48:219-231.
3. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. *Cancer Metastasis Rev.* 2004;23:77-99.
4. Singh BN. Modified release solid formulations for colonic delivery. *Recent Pat Drug Deliv Formul.* 2007;1:53-63.
5. Yang L. Biorelevant dissolution testing of colon-specific delivery systems activated by colonic microflora. *J Control Release.* 2008;125:77-86.
6. Sinha VR, Kumria R. Microbially triggered drug delivery to the colon. *Eur J Pharm Sci.* 2003;18:3-18.
7. Guarner F. Enteric flora in health and disease. *Digestion.* 2006;73(suppl 1):5-12.
8. World Health Organization: Health topics. <http://www.who.int/topics/cancer/en> (2009). Accessed 25 Feb 2009.
9. Boyle P, Leon ME. Recent developments in the epidemiology of colorectal cancer. In: Bleiberg H, Kemeny N, Rougier P, Wilke H, editors. *Colorectal cancer – A clinical guide to therapy.* UK: Taylor and Francis; 2002 chapter 2 p.11-29.
10. Lieberman D. Colorectal cancer screening and surveillance. In: Ginsberg GG, Kochman ML, Norton I, Gostout CJ, editors. *Clinical gastrointestinal endoscopy.* UK: Elsevier; 2005 Chapter 37 p.537-547.
11. Midgley RS, Merrie A, Kerr DJ, Mortensen N. Colorectal cancer: a multidisciplinary approach. In: Weinstein WM, Hawkey CJ, Bosch J, editors. *Clinical gastroenterology and hepatology.* Spain: Elsevier; 2005 Chapter 60D p.421-430.
12. Johnson IT. New approaches to the role of diet in the prevention of cancers of the alimentary



tract. *Mutat Res.* 2004;551:9-28.

13. Yen EF. Colon neoplasms. In: Shiels A, Lin TL, editors. *The Washington Manual™ gastroenterology subspecialty consult*. USA: Lippincott Williams & Wilkins; 2004 Chapter 17 p.93-100.
14. Soetikno R, Friedland S, Matsuda T, Gotoda T. Colonoscopic polypectomy and endoscopic mucosal resection. In: Ginsberg GG, Kochman ML, Norton I, Gostout CJ, editors. *Clinical gastrointestinal endoscopy*. UK: Elsevier; 2005 Chapter 38 p.549-568.
15. Wikipedia. Colorectal cancer. *Wikipedia: the free Encyclopedia*. Accessed 17 Apr 2009.
16. Greenwald P, Clifford CK, Milner JA. Diet and cancer prevention. *Eur J Cancer*. 2001;37:948-965.
17. Benamouzig R. Chemoprevention of colorectal cancer. In: Bleiberg H, Kemeny N, Rougier P, Wilke H, editors. *Colorectal cancer – A clinical guide to therapy*. UK: Taylor and Francis; 2002 chapter 5 p.47-52.
18. Watson AJM. An overview of apoptosis and the prevention of colorectal cancer. *Crit Rev Oncol/Hematol*. 2006;57:107-121.
19. Strate L, Pieramici E, Ahnen D. Biology and genetics of colorectal cancer. In: Weinstein WM, Hawkey CJ, Bosch J, editors. *Clinical gastroenterology and hepatology*. Spain: Elsevier; 2005 Chapter 60A p.397-406.
20. Abramowicz MJ. Biology of colorectal cancer: An overview of genetic factors. In: Bleiberg H, Kemeny N, Rougier P, Wilke H, editors. *Colorectal cancer – A clinical guide to therapy*. UK: Taylor and Francis; 2002 chapter 1 p.3-9.
21. Liu C, Crawford JM. The gastrointestinal tract. In: Kumar V, Abbas AK, Fausto N, editors. *Pathologic basis of disease*. USA: Elsevier; 2005 Chapter 17 p.797-875.
22. Hermanek P. Pathology of colorectal cancer. In: Bleiberg H, Kemeny N, Rougier P, Wilke H, editors. *Colorectal cancer – A clinical guide to therapy*. UK: Taylor and Francis; 2002 p.55-72.

23. Davies JM, Goldberg RM. First-line therapeutic strategies in metastatic colorectal cancer. *Oncology (Huntingt)*. 2008;22:1470-1479.
24. Midgley R. Systemic adjuvant therapy of colon cancer. In: Bleiberg H, Kemeny N, Rougier P, Wilke H, editors. *Colorectal cancer – A clinical guide to therapy*. UK: Taylor and Francis; 2002 Chapter 12 p.127-134.
25. Ammori JB, Kemeny NE. Regional hepatic chemotherapies in treatment of colorectal cancer metastases to the liver. *Semin Oncol*. 2010;37:139-48.
26. Sakamoto J, Oba K, Matsui T, Kobayashi M. Efficacy of oral anticancer agents for colorectal cancer. *Dis Colon Rectum*. 2006;49:S82-S91.
27. National Cancer Institute, US National Institute of Health. Colon cancer treatment (PDQ®). <http://www.cancer.gov/cancertopics/pdq/treatment/colon/HealthProfessional/69.cdr>. Accessed 27 July 2010.
28. Ugurlu T, Turkoglu M, Gurer US, Akarsu BG. Colonic delivery of compression coated nisin tablets using pectin/HPMC polymer mixture. *Eur J Pharm Biopharm*. 2007;67:202-210.
29. Sinha VR, Kumria R. Polysaccharides in colon specific drug delivery. *Int J Pharm*. 2001;224:19-38.
30. Yang L, Chu JS, Fix JA. Colon-specific drug delivery, new approaches and in vitro/in vivo evaluation. *Int J Pharm*. 2002; 235:1-15.
31. Van den Mooter G, Maris B, Samyn C, Augustijns P, Kinget R. Use of azopolymers for colon specific drug delivery. *J Pharm Sci*. 1997;86:1321-1327.
32. Sinha VR, Kumria R. Coating polymers for colon specific drug delivery: a comparative in vitro evaluation. *Acta Pharm*. 2003;53:41-47.
33. Gazzaniga A, Maroni A, Sangalli ME, Zema L. Time-controlled oral delivery systems for colon targeting. *Expert Opin Drug Deliv*. 2006;3:583-597.
34. Shibata N, Ohno T, Shimokawa T, Hu Z, Yoshikawa Y, Koga K, Murakami M, Takada K.

- Application of pressure-controlled colon delivery capsule to oral administration of glycyrrhizin in dogs. *J Pharm Pharmacol*. 2001;53:441-447.
35. Liu CS, Fishman ML, Hicks KB. Pectin in controlled drug delivery - a review. *Cellulose*. 2007;14:15-24.
  36. Liu LS, Fishman ML, Kost J, Hicks KB. Pectin-based systems for colon-specific drug delivery via oral route. *Biomaterials*. 2003;24:3333-3343.
  37. May CD. Pectins. In: Phillips GO, Williams PA, editors. *Handbook of hydrocolloids*. UK: Woodhead Publishing Limited; 2003 Chapter 10 p.169-188.
  38. Ridley BL, O'Neill MA, Mohnen D. Pectins: structure, biosynthesis, and oligogalacturonide-related signaling. *Phytochem*. 2001;57:929-967.
  39. Denev P, Kratchanov Chr. Influence of some cations on the reaction of apple pectin with ammonia in homogeneous media. In: Visser J, Voragen AGJ, editors. *Pectins and pectinases*. Amsterdam: Elsevier; 1996 p.527-540.
  40. Rinaudo M. Physicochemical properties of pectins in solution and gel states. In: Visser J, Voragen AGJ, editors. *Pectins and pectinases*. Amsterdam: Elsevier; 1996 p.21-33.
  41. Sriamornsak P. Chemistry of pectin and its pharmaceutical uses: A review. *Silpakorn Uni Int J*. 2003;3(1-2):206-228.
  42. Moore MA, Park CB, Tsuda H. Soluble and insoluble fiber influences on cancer development. *Crit Rev Oncol/Hematol*. 1998;27:229-242.
  43. Lupton JR. Is fiber protective against colon cancer? Where the research is leading us. *Nutrition*. 2000;16(7/8):558-561.
  44. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. *J Clin Gastroenterol*. 2006;40:235-43.
  45. Ferguson LR, Harris PJ. Studies on the role of specific dietary fibres in protection against colorectal cancer. *Mutat Res*. 1996;350:173-184.

46. Park HS, Choi JS, Kim KH. Docosahexaenoic acid-rich fish oil and pectin have a hypolipidemic effect, but pectin increases risk factor for colon cancer in rats. *Nutr Res.* 2000;20(12):1783-1794.
47. Bauer HG, Asp NG, Oste R. Effect of dietary fiber on the induction of colorectal tumors and fecal  $\beta$ -glucuronidase activity in the rat. *Cancer Res.* 1979;39(9):3752-3756.
48. Bauer HG, Asp NG, Dahigvist A. Effect of two kinds of pectin and guar gum on 1,2-dimethylhydrazine initiation of colon tumors and on fecal  $\beta$ -glucuronidase activity in the rat. *Cancer Res.* 1981;41(6):2518-2523.
49. Ohkami H, Tazawa K, Yamashita I, Shimizu T, Murai K, Kobashi K, Fujimaki M. Effects of apple pectin on fecal bacterial enzymes in azoxymethane-induced rat colon carcinogenesis. *Jpn J Cancer Res.* 1995;86(6):523-529.
50. Tazawa K, Okami H, Yamashita I, Ohnishi Y, Kobashi K, Fujimaki M. Anticarcinogenic action of apple pectin on fecal enzyme activities and mucosal or portal prostaglandin E2 levels in experimental rat colon carcinogenesis. *J Exp Clin Cancer Res.* 1997;16(1):33-38.
51. Olano-Martin E, Rimbach GH, Gibson GR, Rastall RA. Pectin and pecticoligosaccharides induce apoptosis in in vitro human colonic adenocarcinoma cells. *Anticancer Res.* 2003;23(1A):341-346.
52. Heitman DW, Hardman WE, Cameron IL. Dietary supplementation with pectin and guar gum on 1,2-dimethylhydrazine-induced colon carcinogenesis in rats. *Carcinogenesis.* 1992;13(5):815-818.
53. Umar S, Morris AP, Kourouma F, Sellin JH. Dietary pectin and calcium inhibit colonic proliferation in vivo by differing mechanisms. *Cell Prolif.* 2003;36(6):361-375.
54. Nakahara S, Raz A. Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway. *Cancer Metastasis Rev.* 2007;26:605-610.
55. Jacobasch G, Dongowski G, Florian S, Müller-Schmehl K, Raab B, Schmiedl D. Pectin does not

- inhibit intestinal carcinogenesis in APC-deficient Min/+ mice. *J Agri Food Chem.* 2008;56(4):1501-1510.
56. Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. *Carbohydr Res.* 2009;344:1788-1791.
57. Hayashi A, Gillen AC, Lott JR. Effects of daily oral administration of quercetin chalcone and modified citrus pectin on implanted colon-25 tumour growth in balb-c mice. *Altern Med Rev.* 2000;5(6):546-552.
58. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, Raz A. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. *J Natl Cancer Inst.* 2002;94(24):1854-1862.
59. Thirawong N, Nunthanid J, Puttipipatkachorn S, Sriamornsak P. Mucoadhesive properties of various pectins on gastrointestinal mucosa: An *in vitro* evaluation using texture analyzer. *Eur J Pharm Biopharm.* 2007;67:132-140.
60. Liu LS, Fishman ML, Hicks KB, Kende M. Intercation of various pectin formulations with porcine colonic tissues. *Biomaterials.* 2005;26:5907-5916.
61. Dongowski G, Anger H. Metabolism of pectin in the gastrointestinal tract. In: Visser J, Voragen AGJ, editors. *Pectins and pectinases.* Amsterdam: Elsevier; 1996 p.659-666.
62. Saito D, Nakaji S, Fukuda S, Shimoyama T, Sakamoto J, Sugawara K. Comparison of the amount of pectin in the human terminal ileum with the amount of orally administered pectin. *Nutrition.* 2005;21:914-919.
63. Ashford M, Fell J, Attwood D, Sharma H, Woodhead P. Studies on pectin formulations for colonic drug delivery. *J Control Release.* 1994;30:225-232.
64. Wei X, Sun N, Wu B, Yin C, Wu W. Sigmoidal release of indomethacin from pectin matrix tablets: Effect of in situ crosslinking by calcium cations. *Int J Pharm.* 2006;318:132-138.
65. Rubinstein A, Radai R, Ezra M, Pathak S, Rokem JS. In vitro evaluation of calcium pectinate: A

- potential colon-specific drug delivery carrier. *Pharm Res.* 1993;10(2):258-263.
66. Wu B, Deng D, Lu Y, Wu W. Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. *Eur J Pharm Biopharm.* 2008;69:294-302.
  67. El-Gibaly I. Oral delayed-release system based on Zn-pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery. *Int J Pharm.* 2002;232:199-211.
  68. Adkin DA, Kenyon CJ, Itzhack Lerner E, Landau I, Strauss E, Caron D, Penhasi A, Rubinstein A, Wilding IR. The use of scintigraphy to provide “proof of concept” for novel polysaccharide preparations designed for colonic drug delivery. *Pharm Res.* 1997;14(1):103-107.
  69. Ahrabi SF, Madsen G, Dyrstad K, Sande SA, Graffner C. Development of pectin matrix tablets for colonic delivery of model drug ropivacaine. *Eur J Pharm Sci.* 2000;10:43-52.
  70. Wakerly Z, Fell JT, Attwood D, Parkins DA. In vitro evaluation of pectin-based colonic drug delivery systems. *Int J Pharm.* 1996;129:73-77.
  71. Turkoglu M, Ugurlu T. In vitro evaluation of pectin-HPMC compression coated 5-aminosalicylic acid tablets for colonic delivery. *Eur J Pharm Biopharm.* 2002;53:65-73.
  72. Macleod GS, Fell JT, Collett JH. An in vitro investigation into the potential for bimodal drug release from pectin/chitosan/HPMC-coated tablets. *Int J Pharm.* 1999;188:11-18.
  73. Ofori-Kwakye K, Fell JT. Biphasic drug release from film-coated tablets. *Int J Pharm.* 2003;250:431-440.
  74. Ofori-Kwakye K, Fell JT, Sharma HL, Smith A-M. Gamma scintigraphic evaluation of film-coated tablets intended for colonic or biphasic release. *Int J Pharm.* 2004;270:307-313.
  75. Wakerly Z, Fell JT, Attwood D, Parkins D. Studies on drug release from pectin/ethylcellulose film-coated tablets: a potential colonic delivery system. *Int J Pharm.* 1997;153:219-224.
  76. Fernández-Hervás MJ, Fell JT. Pectin/chitosan mixtures as coatings for colon-specific drug

- delivery: an in vitro evaluation. *Int J Pharm.* 1998;169:115-119.
77. Chambin O, Dupuis G, Champion D, Voilley A, Pourcelot Y. Colon-specific drug delivery: Influence of solution reticulation properties upon pectin beads performance. *Int J Pharm.* 2006;321:86-93.
  78. Dupuis G, Chambin O, Génelot C, Champion D, Pourcelot Y. Colonic drug delivery: Influence of crosslinking agent on pectin beads properties and role of the shell capsule type. *Drug Dev Ind Pharm.* 2006;32(7):847-855.
  79. Bourgeois S, Gernet M, Pradeau D, Andremont A, Fattal E. Evaluation of critical formulation parameters influencing the bioactivity of  $\beta$ -lactamases entrapped in pectin beads. *Int J Pharm.* 2006;324:2-9.
  80. Chaurasia M, Chourasia MK, Jain NK, Jain A, Soni V, Gupta Y, Jain SK. Methotrexate bearing calcium pectinate microspheres: A platform to achieve colon-specific drug release. *Curr Drug Deliv.* 2008;5(3):215-219.
  81. Munjeri O, Collett JH, Fell JT. Hydrogel beads based on amidated pectins for colon-specific drug delivery: the role of chitosan in modifying drug release. *J Control Release.* 1997;46:273-278.
  82. Chang KLB, Lin J. Swelling behavior and the release of protein from chitosan-pectin composite particles. *Carbohydr Polym.* 2000;43:163-169.
  83. Hiorth M, Versland T, Heikkilä J, Tho I, Sande SA. Immersion coating of pellets with calcium pectinate and chitosan. *Int J Pharm.* 2006;308:25-32.
  84. Wei H, Qing D, De-Ying C, Bai X, Li-Fang F. Pectin/ethylcellulose as film coatings for colon-specific drug delivery: Preparation and in vitro evaluation using 5-fluorouracil pellets. *PDA J Pharm Sci Technol.* 2007;61(2):121-130.
  85. Wei H, Qing D, De-Ying C, Bai X, Li-Fang F. Study on colon-specific pectin/ethylcellulose film-coated 5-fluorouracil pellets in rats. *Int J Pharm.* 2008;348:35-45.

86. Semdé R, Amighi K, Devleeschouwer MJ, Moës AJ. Studies of pectin HM/Eudragit<sup>®</sup> RL/Eudragit<sup>®</sup> NE film-coating formulations intended for colonic drug delivery. *Int J Pharm.* 2000;197:181-192.
87. Semdé R, Amighi K, Devleeschouwer MJ, Moës AJ. Effect of pectinolytic enzymes on the theophylline release from pellets coated with water insoluble polymers containing pectin HM or calcium pectinate. *Int J Pharm.* 2000;197:169-179.
88. Maestrelli F, Cirri M, Corti G, Mennini N, Mura P. Development of enteric-coated calcium pectinate microspheres intended for colonic drug delivery. *Eur J Pharm Biopharm.* 2008;69:508-518.
89. Chan WA, Boswell CD, Zhang Z. Comparison of the release profiles of a water soluble drug carried by Eudragit-coated capsules in different in-vitro dissolution liquids. *Powder Technol.* 2001;119:26-32.
90. Jain A, Gupta Y, Jain SK. Potential of calcium pectinate beads for target specific drug release to colon. *J Drug Targeting.* 2007;15(4):285-294.
91. Paharia A, Yadav AK, Rai G, Jain SK, Pancholi SS, Agrawal GP. Eudragit-coated pectin microspheres of 5-fluorouracil for colon targeting. *AAPS PharmSciTech.* 2007;8(1):Article 12 E1-E7.
92. Atyabi F, Majzoob S, Iman M, Salehi M, Dorkoosh F. In vitro evaluation and modification of pectinate gel beads containing trimethyl chitosan, as a multi-particulate system for delivery of water-soluble macromolecules to colon. *Carbohydr Polym.* 2005;61(1):39-51.
93. Xi MM, Zhang SQ, Wang XY, Fang KQ, Gu Y. Study on the characteristics of pectin-ketoprofen for colon targeting in rats. *Int J Pharm.* 2005;298:91-97.
94. Wang Q-W, Liu X-Y, Liu L, Feng J, Li Y-H, Guo Z-J, Mei Q-B. Synthesis and evaluation of the 5-fluorouracil-pectin conjugate targeted at the colon. *Med Chem Res.* 2007;16:370-379.
95. Semdé R, Amighi K, Pierre D, Devleeschouwer MJ, Moës AJ. Leaching of pectin from mixed



- pectin/insoluble polymer films intended for colonic drug delivery. *Int J Pharm.* 1998;174:233-241.
96. Hiorth M, Tho I, Sande SA. The formation and permeability of drugs across free pectin and chitosan films prepared by a spraying method. *Eur J Pharm Biopharm.* 2003;56:175-182.
97. Shike M. Diet and lifestyle in the prevention of colorectal cancer: An overview. *Excerpta Medica.* 1999;106(1A):11S-15S.
98. Alabaster O, Tang Z, Shivapurkar N. Dietary fiber and the chemopreventive modulation of colon carcinogenesis. *Mutat Res.* 1996;350:185-197.
99. Guarner F, Malagelada J-R. Gut flora in health and disease. *The Lancet.* 2003;361(9356):512-519.
100. Oscar C, Thompson-Chagoyán OC, Maldonado J, Gil A. Colonization and impact of disease and other factors of intestinal microbiota. *Digestive Dis Sci.* 2007;52:2069-2077.
101. Charalambides D, Segal I. Colonic pH: A comparison between patients with colostomies due to trauma and colorectal cancer. *Am J Gastroenterol.* 1992;87(1):74-78.
102. McDougall CJ, Wong R, Scudera P, Lesser M, DeCosse JJ. Colonic mucosal pH in humans. *Digestive Dis Sci.* 1993;38(3):542-545.
103. Pillay V, Fassihi R. In vitro release modulation from crosslinked pellets for site specific drug delivery to the gastrointestinal tract I. Comparison of pH-responsive drug release and associated kinetics. *J Control Release.* 1999;59:229-242.
104. Pillay V, Fassihi R. In vitro release modulation from crosslinked pellets for site specific drug delivery to the gastrointestinal tract II. Physicochemical characterization of calcium-alginate, calcium pectinate and calcium-alginate-pectinate pellets. *J Control Release.* 1999;59:243-256.
105. Joseph I, Venkataram S. Indomethacin sustained release from alginate-gelatin or pectin-gelatin coacervates. *Int J Pharm.* 1995;126:161-168.
106. Itoh K, Yahaba M, Takahashi A, Tsuruya R, Miyazaki S, Dairaku M, Togashi M, Mikami R,

- Attwood D. In situ gelling xyloglucan/pectin formulations for oral sustained drug delivery. *Int J Pharm.* 2008;356:95-101.
107. Nurjaya S, Wong TW. Effects of microwave on drug release properties of matrices of pectin. *Carbohydr Polym.* 2005;62(3):245-257.
108. Wong TW, Nurjaya S. Drug release property of chitosan-pectinate beads and its changes under the influence of microwave. *Eur J Pharm Biopharm.* 2008;69:176-188.

**Table 1.** Types of pectin-based colon-specific oral drug delivery system.

No.	Type of dosage form	Type of drug	Type of pectin	Formulation mechanism	Reference
<b>Single-unit</b>					
1.	Calcium pectinate tablet	Sodium fluorescein (model drug), indomethacin	Low methoxyl and high methoxyl pectins	Mixing of pectin with varying contents of calcium ions in tablet.	63,64
2.	Calcium pectinate tablet	Indomethacin	Low esterified pectin	Use of calcium pectinate as matrix substance of tablet.	65
3.	Pectin-HPMC-calcium tablet	Indomethacin	High methoxyl pectin	Mixture of pectin, HPMC and calcium salt as matrix substance of tablet.	66
4.	Zinc pectinate tablet	Ketoprofen	Amidated low methoxyl pectin	Ionotropic gelation of pectin with zinc ions into microparticles followed by compression of dry microparticles into tablet with dextran.	67
5.	Eudragit L coated calcium pectinate-pectin tablet	Samaium oxide <sup>152</sup>	-	Tablet made of calcium pectinate and pectin is enteric coated by Eudragit L to target isotope release at ascending colon.	68
6.	Eudragit L coated calcium pectinate-guar gum tablet	Samaium oxide <sup>152</sup>	-	Tablet made of calcium pectinate and guar gum is enteric coated by Eudragit L to target isotope release at ascending and transverse colon.	68
7.	Eudragit L100 coated ethylcellulose-pectin tablet	Ropivacaine	Amidated pectin and high methoxyl pectin	Drug core consists of pectin and ethylcellulose and is coated with Eudragit L100.	69
8.	Pectin coated tablet	Naphthol green B (model drug)	Pectin USP	Pectin as compression coat onto drug core.	70
9.	Pectin-HPMC coated tablet	5-aminosalicylic acid, nisin	Pectin USP	Mixture of pectin and high molecular weight hydroxypropylmethylcellulose (HPMC) as compression coat onto drug core.	28,71
10.	Pectin-chitosan-HPMC coated tablet	Paracetamol	High methoxyl pectin USP	Mixture of pectin, chitosan and HPMC as film coat onto drug core.	72-74
11.	Ethylcellulose-pectin coated tablet	Paracetamol	Pectin USP	Mixing of pectin with hydrophobic ethylcellulose as film coat of tablet.	75
12.	Pectin-chitosan coated tablet	Indomethacin, paracetamol	High methoxyl pectin USP	Pectin-chitosan as inter-polymer complex coat onto drug core.	76
<b>Multiple-unit</b>					
1.	Zinc pectinate beads	Ketoprofen	Amidated low methoxyl pectin	Ionotropic gelation of pectin with zinc ions in low pH aqueous medium to form beads. Low pH reaction medium promotes protonation of carboxylate moiety of pectin, suppresses intermolecular charge-charge repulsion, reduces polymer	77,78


				chain solubility and facilitates polymer conformational ordering. Beads are subsequently introduced in enteric coated capsule.	
2.	Zinc pectinate microparticles	Ketoprofen	Amidated low methoxyl pectin	Ionotropic gelation of pectin with zinc ions to form microparticles.	67
3.	Calcium pectinate beads	Penicillinase ( $\beta$ -lactamase)	Low methoxyl amidated and non-amidated pectins	Ionotropic gelation of pectin with calcium ions into beads.	79
4.	Calcium pectinate microparticles	Methotrexate	-	Ionotropic gelation of pectin with calcium ions into microparticles.	80
5.	Pectinate-chitosan beads	Indomethacin, sulphamethoxazole	Amidated low methoxyl pectin	Coacervation/crosslinking of pectin with chitosan and calcium ions in a single pot process.	81
6.	Pectin-chitosan composite particles	Bovine serum albumin	Low methoxyl pectin	Coacervation/crosslinking of pectin with chitosan and calcium ions in a single pot process.	82
7.	Chitosan/pectin coated pellets	Riboflavin	Low methoxyl pectin	Immersion coating of calcium acetate pellets with pectin followed by chitosan.	83
8.	Pectin-ethylcellulose coated pellets	5-fluorouracil	Low methoxyl pectin	Mixing of pectin with hydrophobic ethylcellulose as film coat of pellets.	84,85
9.	Pectin-Eudragit RL30D coated pellets	Theophylline	High methoxyl pectin	Pectin-Eudragit RL30D as inter-polymer complex coat onto drug core.	86
10.	Aquacoat ECD30, Surelease and Eudragit NE30D, RS30D/HM or LM calcium pectinate coated pellets	Theophylline	High methoxyl (HM) and low methoxyl (LM) pectins	Coating of pellets with Aquacoat ECD30, Surelease and Eudragit NE30D, RS30D containing high methoxyl pectin or low methoxyl calcium pectinate.	87
11.	Eudragit S100 coated calcium pectinate microparticles	Theophylline	Amidated and non-amidated low methoxyl pectins	Crosslinking of pectin with calcium ions into microparticles followed by Eudragit S100 coating onto microparticles by immersion-solvent evaporation technique.	88
12.	Eudragit S100 coated calcium pectinate beads	Theophylline, 5-fluorouracil	Low methoxyl pectin	Crosslinking of pectin with calcium ions into beads followed by Eudragit S100 coating onto beads.	89,90
13.	Eudragit S100 coated pectin microparticles	5-fluorouracil	-	Pectin microparticles are formed by emulsion dehydration technique and subsequently coated by Eudragit S100 via oil-in-oil solvent evaporation method.	91
14.	HM pectin coated LM pectinate beads	Coomassie Brilliant Blue G 250 (model drug)	High methoxyl and low methoxyl pectins	HM pectin as coat onto LM pectinate core.	92

Prodrug					
1.	Pectin-ketoprofen prodrug	Ketoprofen	High esterified pectin	Chemical linking between pectin and drug.	93
2.	Pectin-5-fluorouracil conjugate	5-fluorouracil	High esterified pectin	Chemical linking between pectin and drug.	94


## List of Figures

- Figure 1.** Gastrointestinal tract and its distribution probability of colon cancer.
- Figure 2.** Development of colon cancer by chromosomal and microsatellite instability pathways.
- Figure 3.** Modulation of galectin-3 mediated colon cancer development by pectin.
- Figure 4.** Formulation and design of microflora triggered pectin-based colon-specific oral drug delivery system.
- Figure 5.** Schematic flow of processing technology employed in design of pectin-based colon-specific oral drug delivery system.


## Tablet



## Pellets



### **Beads/Microparticles**




-Matrix wetting by polymeric coating solution followed by filtration, washing and drying of coated matrix

-Salting out of coating polymer onto the surfaces of matrix through its interaction with electrolyte pre-coated onto the matrix

-Immersion of matrix in polymeric coating solution followed by solvent-evaporation using rotary evaporator technique


### **Microparticles**



**Figure 5.** Schematic flow of processing technology employed in design of pectin-based colon-specific oral drug delivery system.



### **Beads/Microparticles**




-Matrix wetting by polymeric coating solution followed by filtration, washing and drying of coated matrix

-Salting out of coating polymer onto the surfaces of matrix through its interaction with electrolyte pre-coated onto the matrix


-Immersion of matrix in polymeric coating solution followed by solvent-evaporation using rotary evaporator technique

### **Microparticles**





**Figure 5.** Schematic flow of processing technology employed in design of pectin-based colon-specific oral drug delivery system.

### Tablet




### Pellets







**Figure 4.** Formulation and design of microflora triggered pectin-based colon-specific oral drug delivery system.



**Figure 3.** Modulation of galectin-3 mediated colon cancer development by pectin.



**Figure 2.** Development of colon cancer by chromosomal and microsatellite instability pathways.



**Figure 1.** Gastrointestinal tract and its distribution probability of colon cancer.